Depatuxizumab mafodotin

[1]Goss G D, et al. Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor[J]. Cancer, 2018, 124 (10) : 2174-2183.|[2]Padovan M, et al. Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO) . Cancers (Basel) . 2021 Jun 3;13 (11) :2773.|[3]von Achenbach C, et al. Depatuxizumab Mafodotin (ABT-414) -induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFRY1068 Phosphorylation. Mol Cancer Ther. 2020 Jun;19 (6) :1328-1339.|[4]Mani L, et al. Efficacy of depatuxizumab mafodotin (ABT-414) in preclinical models of head and neck cancer. Carcinogenesis. 2024 Jul 8;45 (7) :520-526.|[5]Phillips AC, et al. ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope. Mol Cancer Ther. 2016 Apr;15 (4) :661-9.